Akums Drugs and Pharmaceuticals posts Q2 FY25 adjusted PAT at Rs. 66.7 Cr
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Subscribe To Our Newsletter & Stay Updated